Näytä suppeat kuvailutiedot

dc.contributor.authorOwen, Patrick J.
dc.contributor.authorDaly, Robin M.
dc.contributor.authorVia, Jack Dalla
dc.contributor.authorMundell, Niamh L.
dc.contributor.authorLivingston, Patricia M.
dc.contributor.authorRantalainen, Timo
dc.contributor.authorFraser, Steve F.
dc.date.accessioned2019-11-05T12:42:16Z
dc.date.available2019-11-05T12:42:16Z
dc.date.issued2019
dc.identifier.citationOwen, P. J., Daly, R. M., Via, J. D., Mundell, N. L., Livingston, P. M., Rantalainen, T., & Fraser, S. F. (2019). The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i>, <i>10</i>(5), 1036-1044. <a href="https://doi.org/10.1002/jcsm.12446" target="_blank">https://doi.org/10.1002/jcsm.12446</a>
dc.identifier.otherCONVID_30669018
dc.identifier.otherTUTKAID_81407
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/66162
dc.description.abstractBackground: Androgen deprivation therapy (ADT) for prostate cancer (PCa) may prospectively decrease absolute lean mass (LM) and increase absolute fat mass (FM). Given that estimates of LM by dual‐energy X‐ray absorptiometry may be overestimated in obese people, this study examined the influence of adiposity on muscle health in men treated with ADT for PCa. Methods: This cross‐sectional study examined the influence of adiposity on total and appendicular LM (ALM), muscle cross‐sectional (CSA), and muscle strength in 70 men treated with ADT [mean (standard deviation) age, 71 (6) years] for PCa compared with age‐matched PCa (n = 52) and healthy controls (n = 70). Total body LM, FM and ALM, and 66% tibia and radius muscle CSA were quantified by dual‐energy X‐ray absorptiometry and peripheral quantitative computed tomography, respectively. ALM was further divided by height (m2) or body mass index, with muscle CSA expressed as a per cent of total limb CSA. Upper and lower body and back (three‐repetition maximum and dynamometry) muscle strength were expressed per kilogram of body weight. Results: On average, ADT‐treated men had 4.4–6.4 kg greater FM compared with controls (P ≤ 0.014) and there were no differences in total body or ALM. Total body per cent LM and ALMBMI were 3.8–5.4% (P ≤ 0.001) and 7.8–9.4% (P ≤ 0.001) lower, respectively, in ADT‐treated men compared with both controls. Percentage muscle CSA at both sites and muscle strength (except leg) were 3.0–6.0% (P ≤ 0.031) and 15–17% (P ≤ 0.010) lower, respectively, in ADT‐treated men compared with both controls. Conclusions: The findings from this study indicate muscle mass, size, and strength are compromised in men treated with ADT after accounting for their increased adiposity or body size.fi
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherWiley - VCH Verlag GmbH & Co. KGaA
dc.relation.ispartofseriesJournal of Cachexia, Sarcopenia and Muscle
dc.rightsCC BY-NC 4.0
dc.subject.othersarcopenia
dc.subject.otherprostatic neoplasms
dc.subject.otheradipose tissue
dc.titleThe clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-201910304676
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.oppiaineBiomekaniikkafi
dc.contributor.oppiaineGerontologian tutkimuskeskusfi
dc.contributor.oppiaineHyvinvoinnin tutkimuksen yhteisöfi
dc.contributor.oppiaineBiomechanicsen
dc.contributor.oppiaineGerontology Research Centeren
dc.contributor.oppiaineSchool of Wellbeingen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.date.updated2019-10-30T10:15:32Z
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.format.pagerange1036-1044
dc.relation.issn2190-5991
dc.relation.numberinseries5
dc.relation.volume10
dc.type.versionpublishedVersion
dc.rights.copyright© 2019 The Authors Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders
dc.rights.accesslevelopenAccessfi
dc.subject.ysosyöpätaudit
dc.subject.ysoeturauhassyöpä
dc.subject.ysolihassurkastumasairaudet
dc.subject.ysokehonkoostumus
dc.subject.ysorasvakudokset
dc.subject.ysoatrofia
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p678
jyx.subject.urihttp://www.yso.fi/onto/yso/p14843
jyx.subject.urihttp://www.yso.fi/onto/yso/p15977
jyx.subject.urihttp://www.yso.fi/onto/yso/p26989
jyx.subject.urihttp://www.yso.fi/onto/yso/p24382
jyx.subject.urihttp://www.yso.fi/onto/yso/p20904
dc.rights.urlhttps://creativecommons.org/licenses/by-nc/4.0/
dc.relation.doi10.1002/jcsm.12446
dc.type.okmA1


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot

CC BY-NC 4.0
Ellei muuten mainita, aineiston lisenssi on CC BY-NC 4.0